AEON Biopharma Prices Upsized Public Offering With Potential Gross Proceeds Of Up To $43.3 Mln

AEON Biopharma priced an upsized underwritten public offering expected to raise approximately $13.75 million in immediate gross proceeds. The company also indicated potential total gross proceeds of up to about $4 million (article text is truncated after this figure). The announcement is likely to be viewed as mildly dilutive, creating near-term caution around funding and share supply.

Analysis

AEON Biopharma priced an upsized underwritten public offering expected to raise approximately $13.75 million in immediate gross proceeds. The company also indicated potential total gross proceeds of up to about $4 million (article text is truncated after this figure). The announcement is likely to be viewed as mildly dilutive, creating near-term caution around funding and share supply.